Bruker Daltonics and GeneProt Announce Upgrade of GeneProt's Mass Spectrometry Capabilities for its Geneva Proteomics Factory.Business/Technology Editors & Health/Medical Writers BIOWIRE2K BILLERICA, Mass.--(BW HealthWire)--June 3, 2002 Bruker Daltonics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BDAL BDAL Battle Doll Angelic Layer (game) ) and GeneProt(TM), Inc. today announced that GeneProt will upgrade its mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. capabilities at its proteomics factory in Geneva Geneva, canton and city, Switzerland Geneva (jənē`və), Fr. Genève, canton (1990 pop. 373,019), 109 sq mi (282 sq km), SW Switzerland, surrounding the southwest tip of the Lake of Geneva. , Switzerland. In December 2001, GeneProt already received a new UltraFlex(TM) TOF/TOF system from Bruker Daltonics for its Geneva proteomics research laboratory. Now, GeneProt has contracted with Bruker Daltonics to upgrade all of its 45 existing ion trap mass spectrometers to the latest esquire3000plus performance level over the next 4-8 months. This is expected to increase the sensitivity and lower the minimum detection levels for low-abundance proteins dramatically, by up to an order of magnitude A change in quantity or volume as measured by the decimal point. For example, from tens to hundreds is one order of magnitude. Tens to thousands is two orders of magnitude; tens to millions is three orders of magnitude, etc. . Specifically, GeneProt has converted its November 2001 order for six UltraFlex TOF/TOF systems for its planned North Brunswick, New Jersey facility into an order for upgrading its existing Geneva proteomics facility to state-of-the-art performance. Whilst the new facility in New Jersey, USA remains an option, GeneProt has decided to concentrate its existing resources in Geneva, Switzerland for the remainder of 2002. If GeneProt continues with the expansion of its facilities in the U.S. next year, GeneProt will have the option to acquire UltraFlex TOF/TOF systems for New Jersey at that time. Frank Laukien, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bruker Daltonics, commented: "We are pleased to continue to work with our partner GeneProt on even further improving their very impressive proteomics capabilities in Geneva. GeneProt has already tested one of our latest-generation esquire3000plus ion trap systems in Geneva, and they have seen a dramatic sensitivity improvement. We are delighted that GeneProt has again chosen cutting-edge ion trap technology for its state-of-the art proteomics facility in Geneva." ABOUT BRUKER DALTONICS Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion